TransCode Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RNAZ, updated each market day.
RNAZ AI Sentiment
AI predicts TransCode Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About TransCode Therapeutics, Inc. Common Stock
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Sector
Exchange
Market Cap
$7,840,076
Cap Tier
Employees
7
Headquarters
BOSTON, MA
Listed Since
July 9, 2021
RNAZ Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RNAZ Volatility
TransCode Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
